Post the company’s presentation and Q&A at the firm’s healthcare conference, JPMorgan notes that Apellis (APLS) pre-announced, “encouragingly,” Syfovre sales that beat expectations in Q4. The firm, which continues to see an opportunity for Syfovre to capitalize in the near-term on competitor headwinds, keeps an Overweight rating on Apellis shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis Pharmaceuticals Reports Strong Growth and Leadership Changes
- Apellis reports FY24 preliminary U.S. product revenues $709M
- Apellis appoints Keli Walbert to board of directors
- Apellis price target raised to $26 from $24 at RBC Capital
- Unity Biotechnology appoints Grossi as Chief Medical Officer